Imiquimod 5% cream in topical treatment of facial basal cell carcinoma
Introduction: Basal Cell Carcinoma (BCC) is a non-melanocytic skin neoplasm originating from the cells in the basal epidermal layer, hair follicle shell or other skin adnexa. It is the most frequent skin malignancy. Treatment is surgical or nonsurgical. Cases reports: Herein we present 2 patients wi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Srpsko lekarsko drustvo
2015-01-01
|
| Series: | Hospital Pharmacology |
| Subjects: | |
| Online Access: | http://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2015/2334-94921501184G.pdf |
| _version_ | 1828767747628072960 |
|---|---|
| author | Grubor Svetlana D. Tatljak-Vlahović Vesna J. Radojević Biljana P. |
| author_facet | Grubor Svetlana D. Tatljak-Vlahović Vesna J. Radojević Biljana P. |
| author_sort | Grubor Svetlana D. |
| collection | DOAJ |
| description | Introduction: Basal Cell Carcinoma (BCC) is a non-melanocytic skin neoplasm originating from the cells in the basal epidermal layer, hair follicle shell or other skin adnexa. It is the most frequent skin malignancy. Treatment is surgical or nonsurgical. Cases reports: Herein we present 2 patients with superficial type of BCC and actinic keratosis of the face. The patients have been diagnosed by dermoscopy DermLite dermatoscope by 3Gen Inc. manufacturer, and skin biopsy has been performed for histopathological examination. The superficial BCC of the face has been treated with 5% Imiquimod cream once a day for 5 days in a week, during 4 weeks, with erosions and crusts until complete skin restoration. Conclusion: Based on these case reports, it could be concluded that 5% Imiquimod cream is safe and effective treatment for superficial BCC and represents an optimal treatment to achieve good clinical and esthetic effect for the patients. |
| first_indexed | 2024-12-11T07:33:18Z |
| format | Article |
| id | doaj.art-735561b2c460483698e4af3673adf921 |
| institution | Directory Open Access Journal |
| issn | 2334-9492 2334-9492 |
| language | English |
| last_indexed | 2024-12-11T07:33:18Z |
| publishDate | 2015-01-01 |
| publisher | Srpsko lekarsko drustvo |
| record_format | Article |
| series | Hospital Pharmacology |
| spelling | doaj.art-735561b2c460483698e4af3673adf9212022-12-22T01:15:46ZengSrpsko lekarsko drustvoHospital Pharmacology2334-94922334-94922015-01-012118418810.5937/hpimj1501184G2334-94921501184GImiquimod 5% cream in topical treatment of facial basal cell carcinomaGrubor Svetlana D.0Tatljak-Vlahović Vesna J.1Radojević Biljana P.2University of Belgrade, Faculty of Medicine - Clinical Center 'Zemun', Belgrade-Zemun, SerbiaCity Department of Dermatovenerology, BelgradeUniversity of Belgrade, Faculty of Medicine - Clinical Center 'Zemun', Belgrade-Zemun, SerbiaIntroduction: Basal Cell Carcinoma (BCC) is a non-melanocytic skin neoplasm originating from the cells in the basal epidermal layer, hair follicle shell or other skin adnexa. It is the most frequent skin malignancy. Treatment is surgical or nonsurgical. Cases reports: Herein we present 2 patients with superficial type of BCC and actinic keratosis of the face. The patients have been diagnosed by dermoscopy DermLite dermatoscope by 3Gen Inc. manufacturer, and skin biopsy has been performed for histopathological examination. The superficial BCC of the face has been treated with 5% Imiquimod cream once a day for 5 days in a week, during 4 weeks, with erosions and crusts until complete skin restoration. Conclusion: Based on these case reports, it could be concluded that 5% Imiquimod cream is safe and effective treatment for superficial BCC and represents an optimal treatment to achieve good clinical and esthetic effect for the patients.http://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2015/2334-94921501184G.pdfbasal cell carcinomaactinic keratosisimiquimodtoll-like receptor |
| spellingShingle | Grubor Svetlana D. Tatljak-Vlahović Vesna J. Radojević Biljana P. Imiquimod 5% cream in topical treatment of facial basal cell carcinoma Hospital Pharmacology basal cell carcinoma actinic keratosis imiquimod toll-like receptor |
| title | Imiquimod 5% cream in topical treatment of facial basal cell carcinoma |
| title_full | Imiquimod 5% cream in topical treatment of facial basal cell carcinoma |
| title_fullStr | Imiquimod 5% cream in topical treatment of facial basal cell carcinoma |
| title_full_unstemmed | Imiquimod 5% cream in topical treatment of facial basal cell carcinoma |
| title_short | Imiquimod 5% cream in topical treatment of facial basal cell carcinoma |
| title_sort | imiquimod 5 cream in topical treatment of facial basal cell carcinoma |
| topic | basal cell carcinoma actinic keratosis imiquimod toll-like receptor |
| url | http://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2015/2334-94921501184G.pdf |
| work_keys_str_mv | AT gruborsvetlanad imiquimod5creamintopicaltreatmentoffacialbasalcellcarcinoma AT tatljakvlahovicvesnaj imiquimod5creamintopicaltreatmentoffacialbasalcellcarcinoma AT radojevicbiljanap imiquimod5creamintopicaltreatmentoffacialbasalcellcarcinoma |